Statin-induced liver injury involves cross-talk between cholesterol and selenoprotein biosynthetic pathways

Molecular Pharmacology

Volumn 75, Issue 6, 2009, Pages 1421-1429

  Kromer, Andrea ^a   Moosmann, Bernd ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; GLUTATHIONE PEROXIDASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; MEVINOLIN; PEROXIDE; REACTIVE OXYGEN METABOLITE; SELENITE; SELENOPROTEIN;

ARTICLE; BIOSYNTHESIS; CANCER CELL CULTURE; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INDUCED DISEASE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER INJURY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION INITIATION;

CELL LINE, TUMOR; CHOLESTEROL; CYTOTOXINS; GLUTATHIONE PEROXIDASE; HEPATOCYTES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISOENZYMES; LOVASTATIN; PYRIDINES; PYRROLES; REACTIVE OXYGEN SPECIES; SELENOPROTEINS; SIGNAL TRANSDUCTION; TERT-BUTYLHYDROPEROXIDE; THIOREDOXIN-DISULFIDE REDUCTASE;

EID: 66849118996     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.053678     Document Type: Article

References (39)

1. Argo CK, Loria P, Caldwell SH, and Lonardo A (2008) Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 48:662-669.
2. Baker SK (2005) Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve 31:572-580. (Pubitemid 40577779)
3. Bays H (2006) Statin safety: an overview and assessment of the data-2005. Am J Cardiol 97:6C-26C.
4. Bruckert E, Hayem G, Dejager S, Yau C, and Bégaud B (2005) Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients- the PRIMO study. Cardiovasc Drugs Ther 19:403-414. (Pubitemid 43228152)
5. Carlson BA, Novoselov SV, Kumaraswamy E, Lee BJ, Anver MR, Gladyshev VN, and Hatfield DL (2004) Specific excision of the selenocysteine tRNA[Ser]Sec (Trsp) gene in mouse liver demonstrates an essential role of selenoproteins in liver function. J Biol Chem 279:8011-8017. (Pubitemid 38294689)
6. Chong PH, Seeger JD, and Franklin C (2001) Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med 111:390-400. (Pubitemid 32913673)
7. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, and Bernini F (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84:413-428.
8. Diamond AM, Jaffe D, Murray JL, Safa AR, Samuels BL, and Hatfield DL (1996) Lovastatin effects on human breast carcinoma cells. Differential toxicity of an adriamycin-resistant derivative and influence on selenocysteine tRNAS. Biochem Mol Biol Int 38:345-355. (Pubitemid 26258433)
9. Griffith OW (1980) Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 106:207-212. (Pubitemid 11246585)
10. Grünler J, Ericsson J, and Dallner G (1994) Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins. Biochim Biophys Acta 1212:259-277. (Pubitemid 24181668)
11. Hatfield DL, Carlson BA, Xu XM, Mix H, and Gladyshev VN (2006) Selenocysteine incorporation machinery and the role of selenoproteins in development and health. Prog Nucleic Acid Res Mol Biol 81:97-142.
12. 1 to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem 272:13-16.
13. Hoffmann G, Gibson KM, Brandt IK, Bader PI, Wappner RS, and Sweetman L (1986) Mevalonic aciduria-an inborn error of cholesterol and nonsterol isoprene biosynthesis. N Engl J Med 314:1610-1614. (Pubitemid 16118218)
14. Hoffmann GF, Charpentier C, Mayatepek E, Mancini J, Leichsenring M, Gibson KM, Divry P, Hrebicek M, Lehnert W, and Sartor K (1993) Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics 91:915-921. (Pubitemid 23120719)
15. Hoffmann PR and Berry MJ (2005) Selenoprotein synthesis: a unique translational mechanism used by a diverse family of proteins. Thyroid 15:769-775. (Pubitemid 41339257)
16. Jacobson TA (2006) Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 97:44C-51C.
17. Javitt NB (1990) Hep G2 cells as a resource for metabolic studies: lipoprotein, cholesterol, and bile acids. FASEB J 4:161-168. (Pubitemid 20080720)
18. Lankin VZ, Tikhaze AK, Kukharchuk VV, Konovalova GG, Pisarenko OI, Kaminnyi AI, Shumaev KB, and Belenkov YN (2003) Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins. Mol Cell Biochem 249:129-140. (Pubitemid 37021039)
19. Lankin VZ, Ivanova MV, Konovalova GG, Tikhaze AK, Kaminnyi AI, and Kukharchuk VV (2007) Effect of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors and antioxidant vitamins on free radical lipid oxidation in rat liver. Bull Exp Biol Med 143:414-417. (Pubitemid 47456569)
20. Liang SL, Liu H, and Zhou A (2006) Lovastatin-induced apoptosis in macrophages through the Rac1/Cdc42/JNK pathway. J Immunol 177:651-656. (Pubitemid 43939179)
21. Moosmann B, Skutella T, Beyer K, and Behl C (2001) Protective activity of aromatic amines and imines against oxidative nerve cell death. Biol Chem 382:1601-1612. (Pubitemid 33107702)
22. Moosmann B and Behl C (2004a) Selenoprotein synthesis and side-effects of statins. Lancet 363:892-894. (Pubitemid 38368841)
23. Moosmann B and Behl C (2004b) Selenoproteins, cholesterol-lowering drugs, and the consequences: revisiting of the mevalonate pathway. Trends Cardiovasc Med 14:273-281. (Pubitemid 39473306)
24. Moustafa ME, Carlson BA, El-Saadani MA, Kryukov GV, Sun QA, Harney JW, Hill KE, Combs GF, Feigenbaum L, Mansur DB, et al. (2001) Selective inhibition of selenocysteine tRNA maturation and selenoprotein synthesis in transgenic mice expressing isopentenyladenosine-deficient selenocysteine tRNA. Mol Cell Biol 21:3840-3852. (Pubitemid 32466995)
25. Noël B (2004) Autoimmune disease and other potential side-effects of statins. Lancet 363:2000. (Pubitemid 38759663)
26. Palomäki A, Malminiemi K, Malminiemi O, and Solakivi T (1999) Effects of lovastatin therapy on susceptibility of LDL to oxidation during alpha-tocopherol supplementation. Arterioscler Thromb Vasc Biol 19:1541-1548. (Pubitemid 29263026)
27. Ray KK, Cannon CP, and Ganz P (2006) Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials? Am J Cardiol 98:18P-25P. (Pubitemid 44779497)
28. Rederstorff M, Krol A, and Lescure A (2006) Understanding the importance of selenium and selenoproteins in muscle function. Cell Mol Life Sci 63:52-59. (Pubitemid 43100280)
29. Rosenson RS (2004) Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 173:1-12. (Pubitemid 38228462)
30. Saito Y and Takahashi K (2002) Characterization of selenoprotein P as a selenium supply protein. Eur J Biochem 269:5746-5751. (Pubitemid 35365563)
31. Stagnitti MN (2008) Trends in statins utilization and expenditures for the U.S. civilian noninstitutionalized population, 2000 and 2005. Statistical Brief #205. Agency for Healthcare Research and Quality, Rockville, MD.
32. Suzuki T, Kelly VP, Motohashi H, Nakajima O, Takahashi S, Nishimura S, and Yamamoto M (2008) Deletion of the selenocysteine tRNA gene in macrophages and liver results in compensatory gene induction of cytoprotective enzymes by Nrf2. J Biol Chem 283:2021-2030.
33. Tobert JA (2003) Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2:517-526. (Pubitemid 37361744)
34. Topol EJ (2004) Intensive statin therapy-a sea change in cardiovascular prevention. N Engl J Med 350:1562-1564. (Pubitemid 38477782)
35. Wang CY, Liu PY, and Liao JK (2008) Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 14:37-44.
36. Warner GJ, Berry MJ, Moustafa ME, Carlson BA, Hatfield DL, and Faust JR (2000) Inhibition of selenoprotein synthesis by selenocysteine tRNA[Ser]Sec lacking isopentenyladenosine. J Biol Chem 275:28110-29119.
37. Westerink WM and Schoonen WG (2007) Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol In Vitro 21:1581-1591. (Pubitemid 350103536)
38. Woo JT, Nakagawa H, Krecic AM, Nagai K, Hamilton AD, Sebti SM, and Stern PH (2005) Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NF kappa B ligand (RANKL) or tumor necrosis factor-alpha (TNF-alpha). Biochem Pharmacol 69:87-95. (Pubitemid 39592875)
39. Yu MC and Yuan JM (2004) Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 127:S72-S78. (Pubitemid 39423372)